TL;DR
This study used cryo-electron microscopy (cryo-EM) to visualize the binding of the PET tracer flortaucipir to tau filaments from different neurodegenerative diseases. Surprisingly, flortaucipir was found to bind to tau filaments in chronic traumatic encephalopathy (CTE) but not in Alzheimer's disease (AD) or primary age-related tauopathy (PART), suggesting a potential reason for its differential clinical utility.
What Problem Does This Paper Address?
Tauopathies, a group of neurodegenerative diseases characterized by the abnormal aggregation of tau protein, are a major health concern. Positron Emission Tomography (PET) imaging is a crucial tool for monitoring tau pathology in living brains, aiding in diagnosis and tracking disease progression. Flortaucipir is the only FDA-approved PET tracer for visualizing tau aggregation. However, despite its clinical use, the precise structural basis of flortaucipir's binding to different forms of tau filaments has remained unclear. This lack of structural understanding hinders the development of more specific and effective PET ligands. This paper aims to elucidate the structural interactions between flortaucipir and tau filaments from various tauopathies, specifically Alzheimer's disease (AD) and Chronic Traumatic Encephalopathy (CTE), to explain its differential binding patterns observed in clinical settings.
Methods
The researchers employed cryo-electron microscopy (cryo-EM) to determine the high-resolution structures of tau filaments. They isolated tau filaments from postmortem brain tissue of individuals with AD and with primary age-related tauopathy (PART) that also had a co-pathology of CTE. These isolated filaments were then incubated with and without the PET ligand flortaucipir.
Key techniques include:
- Helical Reconstruction: This is a standard cryo-EM method for analyzing filamentous structures, allowing for the determination of atomic-level details. The researchers used RELION software for this process.
- Pronase Treatment: For the PART case, the tau filaments were treated with pronase to potentially increase the accessibility of the binding sites for flortaucipir.
- Difference Imaging: By subtracting the cryo-EM density map of tau filaments without flortaucipir from the map with flortaucipir, the researchers could visualize any additional density attributable to the bound ligand.
Datasets
The study utilized tau filaments extracted from the frontal cortex of an individual with Alzheimer's disease (AD) and from the hippocampus of an individual with primary age-related tauopathy (PART) that also exhibited chronic traumatic encephalopathy (CTE) co-pathology. These are human postmortem brain tissue samples. No new benchmarks or datasets were introduced.
Key Insights and Ideas
- Differential Binding: The most striking finding is that flortaucipir binds to CTE Type I tau filaments but not to paired helical filaments (PHFs) or straight filaments (SFs) from AD or PART. This directly addresses the discrepancy between flortaucipir's clinical utility in AD and its less clear role in CTE.
- 1:1 Stoichiometry in CTE: In CTE Type I filaments, flortaucipir binds in a precise 1:1 molecular ratio with tau, suggesting a specific and well-defined interaction.
- π-π Stacking Mechanism: The binding of flortaucipir to CTE filaments involves a tilted geometry relative to the helical axis, enabling π-π stacking between adjacent flortaucipir molecules. This stacking is crucial for stabilizing the interaction and is consistent with the observed distances between flortaucipir molecules.
- Structural Basis for Differential Binding: The authors hypothesize that the more "open" C-shaped cavity of CTE tau filaments, compared to the "closed" structure of AD tau filaments, is responsible for accommodating flortaucipir, while the AD fold cannot.
Key Results
- Cryo-EM structures of AD and PART tau filaments (PHFs and SFs) with and without flortaucipir showed no significant differences in density, indicating no detectable binding.
- For CTE Type I filaments from the PART case, an additional density was observed when flortaucipir was present. This density was localized adjacent to lysine 353 (K353) and aspartate 358 (D358).
- The binding of flortaucipir to CTE Type I filaments occurred at a 1:1 molecular stoichiometry with tau.
- The binding mode suggests a tilted orientation of flortaucipir molecules, facilitating π-π stacking with an interplanar distance of 3.5 Å.
Limitations and Future Work
- Sub-stoichiometric Binding in AD: The authors propose that flortaucipir might bind to AD tau filaments in very low, sub-stoichiometric amounts, which would be below the detection limit of cryo-EM reconstruction due to averaging. This is offered as a potential explanation for the lack of observed binding in AD samples.
- Fuzzy Coat Hypothesis: While not favored, the possibility that flortaucipir binds to the disordered "fuzzy coat" of tau filaments, which is invisible to cryo-EM, is acknowledged.
- Ambiguity in Binding Mode: At 2.6 Å resolution, the exact binding mode of flortaucipir to CTE filaments still has some ambiguities, with eight possible orientations that cannot be definitively excluded based on the density alone.
- PART Case with CTE Co-pathology: The study examined CTE filaments from a case with PART and CTE co-pathology, not a pure CTE case. While this is a limitation, the authors suggest their findings may still offer insights.
- Future Work: The paper emphasizes the need for more structures of PET ligands bound to amyloid filaments, combined with clinical data, to guide the rational design of new, more specific PET ligands for tauopathies. Understanding the precise interactions that lead to effective in vivo imaging is crucial.
Summary updated